MPT Stock Analysis: Medical Properties Trust | NYSE
REIT - Healthcare Facilities | NYSE, USA | Market Cap: 1.875m USD | 12M Return: -38.2% | US58463J3041 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 40.1M
Qual. Beats: 0
Rev. Trend: 7.4%
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Medical Properties Trust, Inc. (NYSE: MPT) is a self-advised REIT formed in 2003 to acquire and develop net-leased hospital facilities. As of March 31, 2026, the Company operates one of the worlds largest hospital real estate portfolios, with 378 facilities and approximately 38,000 licensed beds across nine countries and three continents. MPTs financing model enables hospital operators to unlock the value of their owned real estate to fund facility improvements, technology upgrades, and other operational investments. The Company is based in Birmingham, Alabama, and was incorporated in 2003 in Maryland.
MPT trades on the NYSE with a small-cap market capitalization of approximately $1,953M USD and has been listed since its 2005 IPO. As a healthcare REIT under the GICS classification, MPT operates in a sector that invests in real estate serving the healthcare industry, including hospitals, medical office buildings, and senior housing, typically generating revenue through long-term triple-net lease structures with operator tenants.
- Steward Health Care bankruptcy triggers rent defaults and writedowns
- Dividend cut signals cash flow stress from tenant distress
- Asset sales and deleveraging reshape hospital REIT balance sheet
| Net Income: -30.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.02 > 0.02 and ΔFCF/TA 0.30 > 1.0 |
| NWC/Revenue: -87.63% < 20% (prev 47.73%; Δ -135.4% < -1%) |
| CFO/TA 0.02 > 3% & CFO 226.8m > Net Income -30.2m |
| Net Debt (9.40b) to EBITDA (1.05b): 8.94 < 3 |
| Current Ratio: 0.31 > 1.5 & < 3 |
| Outstanding Shares: last quarter (598.0m) vs 12m ago -0.46% < -2% |
| Gross Margin: 82.48% > 18% (prev 96.47%; Δ -13.99% > 0.5%) |
| Asset Turnover: 6.82% > 50% (prev 6.11%; Δ 0.71% > 0%) |
| Interest Coverage Ratio: 1.19 > 6 (EBIT TTM 769.4m / Interest Expense TTM 646.6m) |
| A: -0.06 (Total Current Assets 396.6m - Total Current Liabilities 1.29b) / Total Assets 14.7b |
| B: -0.29 (Retained Earnings -4.21b / Total Assets 14.7b) |
| C: 0.05 (EBIT TTM 769.4m / Avg Total Assets 14.9b) |
| D: 0.44 (Book Value of Equity 4.50b / Total Liabilities 10.2b) |
| Altman-Z'' = -0.52 = B |
| DSRI: 0.86 (Receivables 945.9m/1.00b, Revenue 1.02b/925.3m) |
| GMI: 1.17 (GM 96.47% / 82.48%) |
| AQI: 1.61 (AQ_t 0.23 / AQ_t-1 0.15) |
| SGI: 1.10 (Revenue 1.02b / 925.3m) |
| TATA: -0.02 (NI -30.2m - CFO 226.8m) / TA 14.7b) |
| Beneish M = -2.56 (Cap -4..+1) = A |
As of October 17, 2026, the stock is trading at USD 3.01 with a total of 11,773,626 shares traded. Over the past week, the price has changed by -4.14%, over one month by -11.21%, over three months by -36.08% and over the past year by -38.17%.
Current recommended Stop Loss: 2.80 (which is 7% or 1.6 ATR below the current price).
Medical Properties Trust has received a consensus analysts rating of 3.13. Therefore, it is recommended to hold MPT.
- StrongBuy: 0
- Buy: 3
- Hold: 3
- Sell: 2
- StrongSell: 0
| Analysts Target Price | 5.1 | 70.4% |
P/E Forward = 6.6667
P/S = 1.6972
P/B = 0.4766
P/EG = 1.6083
Revenue TTM = 1.02b USD
EBIT TTM = 769.4m USD
EBITDA TTM = 1.05b USD
Long Term Debt = 8.99b USD (from longTermDebt, last quarter)
Short Term Debt = 1.29b USD (from shortTermDebt, last quarter)
Debt = 9.80b USD (from shortLongTermDebtTotal, last quarter) + Leases 95.7m
Net Debt = 9.40b USD (calculated: Debt 9.80b - CCE 396.6m)
Enterprise Value = 11.3b USD (1.88b + Debt 9.80b - CCE 396.6m)
Interest Coverage Ratio = 1.19 (Ebit TTM 769.4m / Interest Expense TTM 646.6m)
EV/FCF = 49.73x (Enterprise Value 11.3b / FCF TTM 226.8m)
FCF Yield = 2.01% (FCF TTM 226.8m / Enterprise Value 11.3b)
FCF Margin = 22.25% (FCF TTM 226.8m / Revenue TTM 1.02b)
Net Margin = -2.96% (Net Income TTM -30.2m / Revenue TTM 1.02b)
Gross Margin = 82.48% ((Revenue TTM 1.02b - Cost of Revenue TTM 178.6m) / Revenue TTM)
Gross Margin QoQ = 42.11% (prev none%)
Tobins Q-Ratio = 0.76 (Enterprise Value 11.3b / Total Assets 14.7b)
Interest Expense / Debt = 6.60% (Interest Expense 646.6m / Debt 9.80b)
Taxrate = 21.0% (US federal default 21%)
NOPAT = 607.8m (EBIT 769.4m * (1 - 21.00%))
Current Ratio = 0.31 (Total Current Assets 396.6m / Total Current Liabilities 1.29b)
Debt / Equity = 2.18 (Debt 9.80b / totalStockholderEquity, last quarter 4.50b)
Debt / EBITDA = 8.94 (Net Debt 9.40b / EBITDA 1.05b)
Debt / FCF = 41.46 (Net Debt 9.40b / FCF TTM 226.8m)
Total Stockholder Equity = 4.58b (last 4 quarters mean from totalStockholderEquity)
RoA = -0.20% (Net Income -30.2m / Total Assets 14.7b)
RoE = -0.66% (Net Income TTM -30.2m / Total Stockholder Equity 4.58b)
RoCE = 5.67% (EBIT 769.4m / Capital Employed (Equity 4.58b + L.T.Debt 8.99b))
RoIC = 4.14% (NOPAT 607.8m / Invested Capital 14.7b)
WACC = 5.57% (E(1.88b)/V(11.7b) * Re(7.43%) + D(9.80b)/V(11.7b) * Rd(6.60%) * (1-Tc(0.21)))
Discount Rate = 7.43% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -50.72 | Cagr: -0.17%
[DCF] Terminal Value 77.97% ; FCFF base≈211.3m ; Y1≈242.2m ; Y5≈356.5m
[DCF] Fair Price = N/A (negative equity: EV 5.36b - Net Debt 9.40b = -4.04b; debt exceeds intrinsic value)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.05 | # QB: 0
Revenue Correlation: 7.36 | Revenue CAGR: 1.60% | SUE: N/A | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.00 | Chg30d=N/A | Revisions=+0% | Analysts=1
EPS current Year (2026-12-31): EPS=0.10 | Chg30d=+75.00% | Revisions=+0% | GrowthEPS=+122.8% | GrowthRev=+6.8%
EPS next Year (2027-12-31): EPS=0.05 | Chg30d=-54.55% | Revisions=-40% | GrowthEPS=-9.1% | GrowthRev=+3.9%
[Analyst] Revisions Ratio: -40% (up=0, down=2)